Biorasi Selects Medidata\'s Cloud-Based Platform for Optimal Trial Operations

Tuesday, March 31, 2015

MIAMI, March 31, 2015 /PRNewswire/ -- Biorasi, a full-service CRO powered by TALOS™, today announced a strategic partnership with Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences. Offering therapeutic expertise in a number of areas, the global CRO has deployed Medidata's electronic data capture (EDC), management and reporting system, Medidata Rave®, to support Biorasi's Phase I through IV global clinical trial business.

Logo - http://photos.prnewswire.com/prnh/20150331/195574LOGO

Photo - http://photos.prnewswire.com/prnh/20150331/195575

"Biorasi's adoption of Rave has greatly benefited our clinical trials process. The dynamic, easy-to-use technology offers our platform TALOS™ the power to do more compared to other EDC systems," says Dr Boris Reznik, Chairman of Biorasi. "We plan to double in growth this year due to the rising demand of Biosimilars and Interchangeables studies from leading pharmaceutical companies around the world. Utilizing enterprise suite technology allows us to fully leverage our core competency of trial optimization."

As a Medidata Services Partner, Biorasi and its customers gain the advantages of a multi-dimensional, full suite of Medidata products to optimize clinical trial operations and save costs, reduce timelines and mitigate risk. In addition to Rave, the CRO is currently working towards gaining accreditations in Medidata's electronic patient-reported outcome (ePRO) solution for patient-centric data capture (Medidata Patient Cloud®), and Medidata's medical coding solution (Medidata Coder®).

"We are very pleased to have Biorasi join the Medidata Partner Ecosystem and look forward to growing and innovating jointly in this very exciting time of emerging Biosimilars development," says Medidata SVP of Global Partner Business, Pat Bernard. "Medidata can support Biorasi's mission of developing and implementing groundbreaking methods of optimizing clinical research with the scalable, flexible and easily configurable nature of the Medidata Clinical Cloud® and help Biorasi in its innovative efforts to deliver successful new treatments for time-critical indications."

About Medidata Solutions

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Investor Contact: Hulus Alpay, Medidata Solutions, (212)-419-1025, halpay@mdsol.com

Media Contact: Nicole Pariser, Medidata Solutions, (212)-659-1069, Email

About Biorasi

Biorasi is an award-winning Clinical Research Optimized™ CRO. From study design to execution success, optimization is engrained in TALOS™ the most robust and innovative operating platform in the industry. Equipped with TALOS™, Biorasi's full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional offices and operations across North America and around the world.

For more information: Biorasi Contact Form

Contact:

Karen Bertoli Chief Marketing Officer

(305) 216 4190

Email

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biorasi-selects-medidatas-cloud-based-platform-for-optimal-trial-operations-300058345.html

SOURCE Biorasi

TOP